BackenVVeno Medical - Warrants (30/05/2023) Overview

enVVeno Medical - Warrants (30/05/2023) Current Cash

Track enVVeno Medical - Warrants (30/05/2023)'s current cash ($2.8M) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Current Cash
$2.84M
38.99% YoYΔ $797000.00 vs prior year quarter

Peer trimmed avg / median

Loading

enVVeno Medical - Warrants (30/05/2023) Current Cash History

Loading

enVVeno Medical - Warrants (30/05/2023) vs. peers: Current Cash Comparison

Loading

enVVeno Medical - Warrants (30/05/2023) Cash Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

enVVeno Medical - Warrants (30/05/2023) (NVNOW) FAQ

As of the most recent data (June 2026), NVNOW shows a current cash of $2.8M. That compares with $2M in the prior-year period — up 39.0% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, NVNOW's current cash is now $2.8M (was $2M) — a 39.0% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether enVVeno Medical - Warrants (30/05/2023) is outperforming or lagging.

Tracking NVNOW's current cash over time shows whether enVVeno Medical - Warrants (30/05/2023) is scaling, shrinking, or reshaping that part of the business. The current reading is $2.8M That compares with $2M in the prior-year period — up 39.0% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this current cash page, Stockcircle has enVVeno Medical - Warrants (30/05/2023)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect current cash (currently $2.8M) with ownership activity and broader fundamentals.

enVVeno Medical - Warrants (30/05/2023)'s current cash is $2.8M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.